Citius Pharmaceuticals Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
41.7%projected annual EPS growth
Analyst Coverage
1analyst covering
FY EPS (est.)
-$1.87next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| 2027 Annual Meeting of Stockholders | 5 Apr 2027 |
Monitoring Framework
Key Performance Indicators
LYMPHIR Net Product Revenue Quarterly1.7MTarget: Sustained commercial growth to address a $400M+ underserved market
LYMPHIR Target Account Formulary Adoption Rate Quarterly83.0%
Consolidated Cash and Cash Equivalents Quarterly4.6MTarget: Sufficient capital to fund operations through November 2026 (including subsequent financings)
Watch Items
- Mino-Lok NDA Submission PathwayTrigger: FDA feedback on Phase 3 trial data and pathway to approvalAction: Monitor regulatory filings and official press releases regarding the timing of the New Drug Application (NDA) submission.
- Consolidated Cash Runway and Dilution RiskTrigger: Cash runway extending only through November 2026Action: Track further capital raises, warrant exercises, or non-dilutive funding at both the Citius Pharma (CTXR) and Citius Oncology (CTOR) levels.
- LYMPHIR Commercial Launch TrajectoryTrigger: Transition from initial channel fill to sustained treatment-driven demandAction: Evaluate quarterly net product revenues and formulary expansion metrics to ensure commercial momentum.
Research as of 20 Jun 2026